AUTHOR=Ye Wenjing , Li Kangguo , Zhao Zeyu , Wu Shenggen , Qu Huimin , Guo Yichao , Abudunaibi Buasiyamu , Chen Wu , Cai Shaojian , Chen Cailin , Lin Jiawei , Xie Zhonghang , Zhan Meirong , Ou Jianming , Deng Yanqin , Chen Tianmu , Zheng Kuicheng 

TITLE=Inactivated vaccine effectiveness against symptomatic COVID-19 in Fujian, China during the Omicron BA.2 outbreak

JOURNAL=Frontiers in Public Health

VOLUME=Volume 11 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2023.1269194

DOI=10.3389/fpubh.2023.1269194

ISSN=2296-2565

ABSTRACT=More than 90% of the Chinese population have completed 2 doses of inactivated COVID-19 vaccines in Mainland China. However, after China government abandoned strict control measures, many breakthrough infections appeared, and vaccine effectiveness against Omicron BA.2 infection was uncertain. This study aims to investigate the real-world effectiveness of widely used inactivated vaccines during the wave of Omicron variants.Test-negative case-control study was conducted in this study to analyze the vaccine effectiveness against symptomatic disease caused by the Omicron variant (BA.2) in Fujian, China. Conditional logistic regression was selected to estimate the vaccine effectiveness.The study found the vaccine effectiveness against symptomatic COVID-19 is 32% (95% CI, 8% to 50%) at 2 to 8 weeks, and 27% (95% CI, 1% to 46%) at 12 to 24 weeks after receiving booster doses of the inactivated vaccine. Notably, the 3-17 years group had higher vaccine effectiveness after 2 doses than the 18-64 years and over 65 years groups who received booster doses.Inactivated vaccines alone may not offer sufficient protection for all age groups before the summer of 2022. To enhance protection, other types of vaccines or bivalent vaccines 38 should be considered.